0001562180-23-003920.txt : 20230503
0001562180-23-003920.hdr.sgml : 20230503
20230503182608
ACCESSION NUMBER: 0001562180-23-003920
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20230501
FILED AS OF DATE: 20230503
DATE AS OF CHANGE: 20230503
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Russell Alan J
CENTRAL INDEX KEY: 0001853529
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-40236
FILM NUMBER: 23885768
MAIL ADDRESS:
STREET 1: 3415 COLORADO AVE
CITY: BOULDER
STATE: CO
ZIP: 80303
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Edgewise Therapeutics, Inc.
CENTRAL INDEX KEY: 0001710072
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 821725586
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 1715 38TH ST
CITY: BOULDER
STATE: CO
ZIP: 80301
BUSINESS PHONE: 720-262-7002
MAIL ADDRESS:
STREET 1: 1715 38TH ST
CITY: BOULDER
STATE: CO
ZIP: 80301
4
1
primarydocument.xml
PRIMARY DOCUMENT
X0407
4
2023-05-01
false
0001710072
Edgewise Therapeutics, Inc.
EWTX
0001853529
Russell Alan J
C/O EDGEWISE THERAPEUTICS, INC.
3145 COLORADO AVE.
BOULDER
CO
80303
true
true
false
false
Chief Scientific Officer
false
Common Stock
2023-05-01
4
M
false
5208.00
0.00
A
177793.00
D
Common Stock
2023-05-02
4
S
false
1602.00
8.9049
D
176191.00
D
Restricted Stock Units
0.00
2023-05-01
4
M
false
5208.00
0.00
D
2032-05-01
Common Stock
5208.00
10417.00
D
Represents the number of shares sold to cover the statutory tax withholding obligations in connection with the vesting of Restricted Stock Units (RSUs). This sale satisfies the minimum statutory tax withholding obligations to be funded by a "sell-to-cover" transaction and does not represent a discretionary sale by the Reporting Person
The price reported in column 4 is an average price. These shares were sold in multiple transactions at prices ranging from $8.59 to $9.58, inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
RSUs granted to the reporting person which represent a contingent right to receive one share of Edgewise Therapeutics, Inc. common stock upon the vesting of these RSUs in three equal annual installments beginning on May 1, 2023.
/s/ John R. Moore, Attorney-in-Fact for Russell Alan J
2023-05-03